People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.8M | 2021 |
Simon Read at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simon Read on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Christopher O'Donnell | 1 | 8 |
| David Grayzel | 1 | 6 |
| Andrew Hedin | 1 | 5 |
| Lorence Kim | 1 | 5 |
| Milind Deshpande | 1 | 4 |
| Jigar Raythatha | 1 | 2 |
| Nathaniel Brooks Horwitz | 1 | 1 |
| Patrick Trojer | 1 | 1 |
| Christopher O'Donnel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.